kims involvement was to secure the interim analysis and that was secured.
enrollments are handled by Molly Wade.
FDA issues handled by Debra Krinder head of regulatory
either way , was a good move to bring in kim and wish her the best in her future.
lets hope for no drama with the stock tomorrow
kim olesson leaves position head of clinical affairs, page-3
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)